Paper328129
VM 26 and VP 16-213: a comparative analysis.
Rozencweig M and 3 others. Cancer, 1977. Cited by 161 papers, by iCite.
Cite this record
ConductScience Library. VM 26 and VP 16-213: a comparative analysis. Papers, record 328129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/328129
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Podophyllotoxin | Major topic |
| Animals | |
| Brain Neoplasms | |
| Drug Evaluation | |
| Etoposide | |
| Humans | |
| Kinetics | |
| Leukemia | |
| Lung Neoplasms | |
| Lymphoma | |
| Neoplasms, Experimental | |
| Teniposide | |
| Urinary Bladder Neoplasms |
Source PubMed
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 161 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 15139794 | Pharmacokinetic optimisation of treatment with oral etoposide. | Clin Pharmacokinet | 2004 | https://conductscience.org/library/papers/15139794 | PubMed |
| 10789823 | Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. | Drug Saf | 2000 | https://conductscience.org/library/papers/10789823 | PubMed |
| 8699237 | Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. | J Neurooncol | 1996 | https://conductscience.org/library/papers/8699237 | PubMed |
| 8339387 | Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8339387 | PubMed |
| 8070033 | Schedule-dependent topoisomerase II-inhibiting drugs. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070033 | PubMed |
| 8070021 | Teniposide: overview of its therapeutic potential in adult cancers. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070021 | PubMed |
| 7378272 | Effects of monocytopenia and anticoagulation in experimental Streptococcus sanguis endocarditis. | Br J Exp Pathol | 1980 | https://conductscience.org/library/papers/7378272 | PubMed |
| 7083457 | A phase I trial of continuous infusion VP16-213 (etoposide). | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083457 | PubMed |
| 7083454 | Pharmacokinetics of VP16-213 given by different administration methods. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083454 | PubMed |
| 7083453 | Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083453 | PubMed |
| 7044595 | VM26: phase I and II studies. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044595 | PubMed |
| 7044594 | VP16-213 (etoposide). A critical review of its activity. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044594 | PubMed |
| 7044592 | The clinical pharmacology of VM26 and VP16-213. A brief overview. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044592 | PubMed |
| 7031350 | [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. | Klin Wochenschr | 1981 | https://conductscience.org/library/papers/7031350 | PubMed |
| 6678864 | Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6678864 | PubMed |
| 6488441 | Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6488441 | PubMed |
| 6282486 | VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6282486 | PubMed |
| 4017164 | Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/4017164 | PubMed |
| 3815721 | The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3815721 | PubMed |
| 3581418 | In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3581418 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/328129
GET https://conductscience.org/api/papers/v1/328129/cited_by?page=2